Clinical Trial Update: Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo [Phase 2]

View source ↗

Summary

Phase 2 allergen challenge trial comparing single-dose intranasal GSK1004723 to placebo in allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• GSK1004723

Snippet

Sponsor: GlaxoSmithKline | Conditions: Allergic Rhinitis | Phase 2 | Status: COMPLETED